Symbols

KPTI

Karyopharm·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About KPTI

Karyopharm Therapeutics Inc.

A commercial-stage pharmaceutical company pioneering novel cancer therapies

Industry

Biological Technology

Established Date

12/22/2008

Listing Date

11/06/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

228

Fiscal Year Ends

12-31

Website

www.karyopharm.com

Security Type

Common stock

Office address

85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459

Business

Introduction

Karyopharm Therapeutics Inc., was incorporated in Delaware on December 22, 2008. The company is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-line drugs targeting nuclear transport targets for the treatment of cancer and critical diseases. The company's scientific expertise focuses on understanding the regulation of intracellular transport between the nucleus and cytoplasm.

Company Financials

EPS

KPTI has released its 2025 Q4 earnings. EPS was reported at -5.69, versus the expected -0.21, missing expectations. The chart below visualizes how KPTI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

KPTI has released its 2025 Q4 earnings report, with revenue of 34.08M, reflecting a YoY change of 11.58%, and net profit of -102.20M, showing a YoY change of -232.03%. The Sankey diagram below clearly presents KPTI's revenue sources and cost distribution.